Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3117873rdf:typepubmed:Citationlld:pubmed
pubmed-article:3117873lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C0678108lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C0025326lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C0733758lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C0429468lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C0033213lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C1998793lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C0449450lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C1880177lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C1550605lld:lifeskim
pubmed-article:3117873lifeskim:mentionsumls-concept:C0456205lld:lifeskim
pubmed-article:3117873pubmed:issue5lld:pubmed
pubmed-article:3117873pubmed:dateCreated1987-12-17lld:pubmed
pubmed-article:3117873pubmed:abstractTextA preparation of HMG purified to contain only FSH (FSH 75 IU/LH less than 1 IU) was used in 26 patients who had anovulatory sterility because of sclero-polycystic ovaries. It was a selected population in that all the patients had proved to be resistant to Clomiphene Citrate and at risk with HMG therapy. Purified urinary FSH was used and monitored as classical HMG treatment. 44 treatment cycles resulted in 33 ovulatory cycles (75%) and 6 pregnancies (13.6% per cycle). The number of cases of hyperstimulation (13.6%) was low when it is compared to situations at risk when HCG was administered in 2/3 of the treatment cycles. The results obtained in a population with a bad prognosis can be considered to be very encouraging and gives purified urinary FSH a specific place in our therapeutic armamentarium.lld:pubmed
pubmed-article:3117873pubmed:languagefrelld:pubmed
pubmed-article:3117873pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3117873pubmed:citationSubsetIMlld:pubmed
pubmed-article:3117873pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3117873pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3117873pubmed:statusMEDLINElld:pubmed
pubmed-article:3117873pubmed:issn0368-2315lld:pubmed
pubmed-article:3117873pubmed:authorpubmed-author:EmperaireJ...lld:pubmed
pubmed-article:3117873pubmed:authorpubmed-author:AudebertA JAJlld:pubmed
pubmed-article:3117873pubmed:authorpubmed-author:RuffiéAAlld:pubmed
pubmed-article:3117873pubmed:issnTypePrintlld:pubmed
pubmed-article:3117873pubmed:volume16lld:pubmed
pubmed-article:3117873pubmed:ownerNLMlld:pubmed
pubmed-article:3117873pubmed:authorsCompleteYlld:pubmed
pubmed-article:3117873pubmed:pagination621-6lld:pubmed
pubmed-article:3117873pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3117873pubmed:meshHeadingpubmed-meshheading:3117873-...lld:pubmed
pubmed-article:3117873pubmed:meshHeadingpubmed-meshheading:3117873-...lld:pubmed
pubmed-article:3117873pubmed:meshHeadingpubmed-meshheading:3117873-...lld:pubmed
pubmed-article:3117873pubmed:meshHeadingpubmed-meshheading:3117873-...lld:pubmed
pubmed-article:3117873pubmed:meshHeadingpubmed-meshheading:3117873-...lld:pubmed
pubmed-article:3117873pubmed:meshHeadingpubmed-meshheading:3117873-...lld:pubmed
pubmed-article:3117873pubmed:meshHeadingpubmed-meshheading:3117873-...lld:pubmed
pubmed-article:3117873pubmed:meshHeadingpubmed-meshheading:3117873-...lld:pubmed
pubmed-article:3117873pubmed:year1987lld:pubmed
pubmed-article:3117873pubmed:articleTitle[Contribution of human menopausal gonadotropins purified as to their FSH content in anovulatory sterility presenting a difficult treatment problem].lld:pubmed
pubmed-article:3117873pubmed:affiliationInstitut R. Greenblatt, Bordeaux.lld:pubmed
pubmed-article:3117873pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3117873pubmed:publicationTypeEnglish Abstractlld:pubmed